The hidden secrets of soluble RANKL in bone biology
- PMID: 33994070
- DOI: 10.1016/j.cyto.2021.155559
The hidden secrets of soluble RANKL in bone biology
Abstract
The discovery of cytokine tumor necrosis factor (TNF) in the 20th century revealed numerous secrets about organ development. In particular, the functions identified for the receptor activator of nuclear factor kappa-β (NF-κβ) ligand (also known as the RANKL/osteoprotegerin ligand (OPGL) or RANK ligand/TNFSF11) in the homeostasis of skeletal structure, function and regulation were not anticipated. Empirical evidence established the receptor-ligand interaction of RANKL with RANK in osteoclast formation. Reverse signaling of RANKL triggers NF-κβ for the degradation of β-catenin to inhibit bone formation. There is also evidence that RANKL modifies the behavior of other cells in the bone microenvironment, including osteoblasts, chondrocytes, endothelial cells and lymphocytes during normal (homeostatic) and diseased (osteoimmune) states. Two forms of RANKL, i.e., soluble and membrane-bound RANKL, are produced by bone cells. Even though soluble RANKL (sRANKL) and membrane-bound RANKL (mRANKL) both stimulate osteoclast formation in vitro, their biological roles are different. mRANKL triggers osteoclastogenesis by binding to RANK through cell-cell interaction; however, sRANKL released from osteogenic cells binds to RANK without cell-cell interaction. This review attempts to hypothesize how sRANKL functions biologically in bone and explore how this hypothesis might influence future research.
Keywords: Bone formation; Bone resorption; Signaling mechanism; Soluble RANKL.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Similar articles
-
Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.Bone. 1999 Nov;25(5):517-23. doi: 10.1016/s8756-3282(99)00210-0. Bone. 1999. PMID: 10574571
-
A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.Biochem Biophys Res Commun. 1999 Mar 24;256(3):449-55. doi: 10.1006/bbrc.1999.0252. Biochem Biophys Res Commun. 1999. PMID: 10080918 Review.
-
Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture.Bone. 2001 May;28(5):474-83. doi: 10.1016/s8756-3282(01)00420-3. Bone. 2001. PMID: 11344046
-
Soluble RANKL Cleaved from Activated Lymphocytes by TNF-α-Converting Enzyme Contributes to Osteoclastogenesis in Periodontitis.J Immunol. 2016 Nov 15;197(10):3871-3883. doi: 10.4049/jimmunol.1601114. Epub 2016 Oct 7. J Immunol. 2016. PMID: 27815441 Free PMC article.
-
Action of RANKL and OPG for osteoclastogenesis.Crit Rev Eukaryot Gene Expr. 2009;19(1):61-72. doi: 10.1615/critreveukargeneexpr.v19.i1.30. Crit Rev Eukaryot Gene Expr. 2009. PMID: 19191757 Review.
Cited by
-
The Molecular Mechanisms Study of Engeletin Suppresses RANKL-Induced Osteoclastogenesis and Inhibits Ovariectomized Murine Model Bone Loss.J Inflamm Res. 2023 May 24;16:2255-2270. doi: 10.2147/JIR.S401519. eCollection 2023. J Inflamm Res. 2023. PMID: 37250105 Free PMC article.
-
Membrane-free stem cell components suppress osteoclast differentiation: Implications for oral regenerative treatment.J Dent Sci. 2025 Jan;20(1):212-219. doi: 10.1016/j.jds.2024.08.005. Epub 2024 Aug 19. J Dent Sci. 2025. PMID: 39873034 Free PMC article.
-
Evaluation of Anti-SARS-CoV-2 IgG Responses in a Clinical Study of a Biosimilar Candidate to Denosumab Using Singlicate Analysis.Drugs R D. 2025 Jun;25(2):141-152. doi: 10.1007/s40268-025-00510-z. Epub 2025 May 23. Drugs R D. 2025. PMID: 40408051 Free PMC article.
-
Receptor activator of nuclear factor-κB ligand and tumor necrosis factor-α promotes osteoclast differentiation through the exosomes of inflammatory periodontal ligament stem cells.Hua Xi Kou Qiang Yi Xue Za Zhi. 2022 Jul 25;40(4):377-385. doi: 10.7518/hxkq.2022.04.002. Hua Xi Kou Qiang Yi Xue Za Zhi. 2022. PMID: 38596952 Free PMC article. Chinese, English.
-
Mechanistic advances in osteoporosis and anti-osteoporosis therapies.MedComm (2020). 2023 May 11;4(3):e244. doi: 10.1002/mco2.244. eCollection 2023 Jun. MedComm (2020). 2023. PMID: 37188325 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources